AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Blood Cancer

Trial Identifier: D8230C00002
Sponsor: AstraZeneca
Collaborator:
Parexel International
NCTID:: NCT04630756
Start Date: February 2021
Primary Completion Date: September 2023
Study Completion Date: December 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Clayton, AU, 3168
AU Nedlands, AU, 6009
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H3T 1E2
CA, QC Quebec, QC, CA, G1R 2J6
DE Essen, DE, 45147
DE Homburg, DE, 66421
DE Muenster, DE, 48149
DE Munchen, DE, 81377
ES Barcelona, ES, 08035
ES Madrid, ES, 28040
ES Palma de mallorca, ES, 07120
FR LILLE CEDEX, FR, 59037
FR Rouen, FR, 76038
GB Glasgow, GB, G12 0YN
GB Plymouth, GB, PL6 8DH
GB Sutton, GB, SM2 5PT
IE Dublin, IE, D08 NHY1
IE Galway, IE, H91 YR71
IT Brescia, IT, 25123
IT Modena, IT, 41124
IT Monza, IT, 20900
IT Rozzano, IT, 20089
KR Seoul, KR, 06351
KR Seoul, KR, 05505
KR Seoul, KR, 03080
PL Katowice, PL, 40-519
PL Kraków, PL, 30-510
PL Lublin, PL, 20-059
PL Warszawa, PL, 02-781
PL Wroclaw, PL, 50-367
US, CA Duarte, CA, US, 91010
US, California La Jolla, California, US, 92093-0052
US, FL Tampa, FL, US, 33612
US, GA Atlanta, GA, US, 30322
US, NJ Hackensack, NJ, US, 07601
US, OH Columbus, OH, US, 43202
US, TX Houston, TX, US, 77030
US, UT Salt Lake City, UT, US, 84112
US, WA Seattle, WA, US, 98104